Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection

References

• Harris RJ, Ramsay M, Hope VD, et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health 2012;22:187-92
   PubMed Web of Science ®Google Scholar
• Bruggmann P, Berg T, Ovrehus ALH, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepatitis 2014;21(Suppl 1):5-33
   PubMed Web of Science ®Google Scholar
• Brant LJ, Ramsay ME, Tweed E, et al.; Sentinel Surveillance of Hepatitis Testing Group. Planning for the healthcare burden of hepatitis C infection: hepatitis C genotypes identified in England, 2002-2007. J Clin Virol 2010;48:115-9
   PubMed Web of Science ®Google Scholar
• Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-62
   PubMed Web of Science ®Google Scholar
• Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int 2009;29(1 Suppl):89-99
   PubMed Web of Science ®Google Scholar
• Stahmeyer JT, Rosol S, Bert F, et al. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur J Gastroenterol Hepatol 2014;26:1278-85
   PubMed Web of Science ®Google Scholar
• Xu T, Tong X, Leidner AJ. Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Aff (Millwood) 2014;33:1728-35
   PubMed Web of Science ®Google Scholar
• Tandon N, Balart LA, Laliberte F, et al. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. J Med Econ 2014;17:862-71
   PubMedGoogle Scholar
• Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm 2013;19:438-47
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-xii, 1–210
   PubMed Web of Science ®Google Scholar
• McDonald SA, Hutchinson SJ, Bird SM, et al. The growing contribution of hepatitis C virus infection to liver-related mortality in Scotland. Euro Surveill 2010;15:19562
   PubMedGoogle Scholar
• Neal KR, Trent Hepatitis C Study Group, Ramsay S, et al. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007;56:1098-104
   PubMed Web of Science ®Google Scholar
• McDonald SA, Hutchinson SJ, Bird SM, et al. A record linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. Br J Cancer 2008;99:805-10
   PubMed Web of Science ®Google Scholar
• McDonald SA, Hutchinson SJ, Bird SM, et al. Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study. Eur J Gastroenterol Hepatol 2010;22:49-57
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
   PubMed Web of Science ®Google Scholar
• Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries. BMC Gastroenterol 2013;13:16
   PubMed Web of Science ®Google Scholar
• Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011;52:889-900
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504-08
   PubMed Web of Science ®Google Scholar
• Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-8
   PubMed Web of Science ®Google Scholar
• Papastergiou V, Stampori M, Lisgos P, et al. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastroenterol Hepatol 2013;25:798-805
   PubMed Web of Science ®Google Scholar
• Koh C, Heller T, Haynes-Williams V, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013;37:887-94
   PubMed Web of Science ®Google Scholar
• Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:iii-iv, 1–125
   PubMedGoogle Scholar
• Yang D, Liang HJ, Li D, et al. The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials. Intern Med 2013;52:653-60
   PubMed Web of Science ®Google Scholar
• Ferenci P, Reddy KR. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Antivir Ther 2011;16:1187-201
   PubMed Web of Science ®Google Scholar
• Druyts E, Lorenzi M, Toor K, et al. Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. QJM 2015;108:299-306
   PubMed Web of Science ®Google Scholar
• Welch NM, Jensen DM. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int 2015;35(1 Suppl):11-17
   PubMed Web of Science ®Google Scholar
• Sharma SA, Feld JJ. Management of HCV in cirrhosis- a rapidly evolving landscape. Curr Gastroenterol Rep 2015;17:443
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63:199-236
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (ISDA). Recommendations for testing, managing, and treating hepatitis C [Internet]. 2016. http://www.hcvguidelines.org. Accessed April 19, 2016
   Google Scholar
• Feld J, Kowdley K, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al.; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-92
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson I, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14
   PubMed Web of Science ®Google Scholar
• Andreone P, Colombo M, Enejosa J, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359-65
   PubMed Web of Science ®Google Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-205
   PubMed Web of Science ®Google Scholar
• Grishchenko M, Grieve RD, Sweeting MJ, et al.; Trent HCV Study Group. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-80
   PubMed Web of Science ®Google Scholar
• Harris KA, Gilham C, Mortimer PP, et al. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999;58:127-31
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Simeprevir for the treatment of genotype 1 and genotype 4 chronic hepatitis C [Single Technology Appraisal ID668], 18 September 2014. https://www.nice.org.uk/guidance/TA331/documents/hepatitis-c-chronic-simeprevir-id668-evaluation-report2. Last accessed May 18, 2016
   Google Scholar
• Wright M, Grieve R, Roberts J, et al.; UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113
   Web of Science ®Google Scholar
• Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-8
   PubMed Web of Science ®Google Scholar
• Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72
   PubMed Web of Science ®Google Scholar
• Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65
   PubMed Web of Science ®Google Scholar
• Backx M, Lewszuk A, White JR, et al. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat 2014;21:208-15
   PubMed Web of Science ®Google Scholar
• Foster GR, Goldin RD, Main J, et al. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997;315:453-8
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, C Bacon BR, et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al.; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
   PubMed Web of Science ®Google Scholar
• Monthly Index of Medical Specialties (MIMS) [Internet]. Available at http://www.mims.co.uk/. Last accessed May 24, 2014
   Google Scholar
• Curtis L. Unit costs of health and social care. Personal Social Services Research Unit, 2013
   Google Scholar
• Thorlund K, Druyts E, El Khoury AC, et al. Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. Clinicoecon Outcomes Res 2012;4:349-59
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence (NICE). Sofosbuvir for chronic hepatitis C, 18 March, 2014. https://www.nice.org.uk/guidance/TA330/documents/hepatitis-c-chronic-sofosbuvir-evaluation-report4. Last accessed May 18, 2016
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Depression: the treatment and management of depression in adults (updated edition). Clinical Practice Guideline 90. British Psychological Society, Leicester, UK and the Royal College of Psychiatrists, London, UK, 2010
   Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014;60:741-7
   PubMed Web of Science ®Google Scholar
• Thein HH, Yo Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-38
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16
   PubMed Web of Science ®Google Scholar
• Saab S, Parisé H, Virabhak S, et al. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the United States. J Med Econ 2016:1-42
   PubMedGoogle Scholar
• Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterology 2015;15:98
   PubMed Web of Science ®Google Scholar
• Saab S, Gordon SC, Park M, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-75
   PubMed Web of Science ®Google Scholar
• Petta S, Cabibbo G, Enea M, et al.; WEF Study Group. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59:1692-705
   PubMed Web of Science ®Google Scholar
• San Miguel R, Gimeno-Ballester, Mar J. Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Rev Pharmacoecon Outcomes Res 2014;14:387-402
   PubMed Web of Science ®Google Scholar
• Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014;46(5 Suppl):S186-S96
   Google Scholar
• Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One 2015;10:e0126984
   PubMed Web of Science ®Google Scholar
• National Health Service (NHS) England Clinical Reference Group for Infectious Diseases. Clinical commissioning policy statement: treatment of chronic hepatitis C in patients with cirrhosis [Internet]. National Health Services, 2015. Presented at HepDART 2011, Kauai, HI, USA, December 4–8. http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-cirrhosis-polcy-statmnt-0615.pdf. Accessed October 6, 2015
   Google Scholar
• Kauffman RS, Muir AJ, Nelson DR, et al. Review activity/safety: telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response in genotype 1 chronic HCV. Conference reports for the National AIDS Treatment Advocacy Project. 2011. Presented at HepDART 2011, Kauai, HI, USA, December 4–8. http://www.natap.org/2011/hepDART/hepDART_03.htm. Accessed October 6, 2015
   Google Scholar